Cancer clinical trials in the region Centre-Val de Loire

48 currently recruiting clinical trials
Region Centre-Val de Loire

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
6 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
7 main criterias to confirm
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
8 main criterias to confirm
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
8 main criterias to confirm
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
8 main criterias to confirm
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
7 main criterias to confirm
AstraZeneca
Phase 3 Kidney cancer
#NCT06364631
Clear cell carcinoma Metastatic None 0 1 or 2 Systemic Treatment-Naive
7 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lung cancer
#NCT05899608
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Metastatic Systemic Treatment-Naive
ALK EGFR ROS-1
8 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
Summit Therapeutics
Phase 3 Prostate cancer
#NCT06120491
Metastatic Hormone-sensitive Other mutation Surgery Radiotherapy Systemic Treatment-Naive
8 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
AstraZeneca
Phase 3 Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Negative (< 1%) None Systemic Treatment-Naive
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
11 main criterias to confirm
Centre Hospitalier Régional Universitaire de Tours (Tours)
Amgen